

Kebede Begna

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8488548/kebede-begna-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

1,302
citations

17
h-index

34
g-index

139
ext. papers

1,779
ext. citations

4.8
avg, IF

4.19
L-index

#	Paper	IF	Citations
130	Molecular markers demonstrate diagnostic and prognostic value in the evaluation of myelodysplastic syndromes in cytopenia patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 12	7	
129	European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response.. <i>Blood Cancer Journal</i> , 2022 , 12, 7	7	1
128	Midostaurin therapy for indolent and smoldering systemic mastocytosis: retrospective review of Mayo Clinic experience.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
127	Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients.. <i>Blood Cancer Journal</i> , 2022 , 12, 26	7	1
126	-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.. <i>Haematologica</i> , 2022 ,	6.6	1
125	Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases.. <i>American Journal of Hematology</i> , 2022 ,	7.1	2
124	Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0
123	Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.. <i>American Journal of Hematology</i> , 2022 ,	7.1	1
122	Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3" .. <i>Blood Cancer Journal</i> , 2022 , 12, 55	7	1
121	Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T.. <i>American Journal of Hematology</i> , 2021 ,	7.1	2
120	Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases. <i>British Journal of Haematology</i> , 2021 ,	4.5	3
119	A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML. <i>Blood</i> , 2021 , 138, 3423-3423	2.2	
118	Outcome of Therapy-Related Myeloid Neoplasms with Venetoclax-Based Therapy. <i>Blood</i> , 2021 , 138, 36-36	2.2	
117	Anthracycline Choices for Induction Chemotherapy Among 797 Consecutive Adult Patients with Acute Myeloid Leukemia: Daunorubicin-60 Vs Idarubicin-12 Vs Daunorubicin-90. <i>Blood</i> , 2021 , 138, 1267-1267	2.2	
116	Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents. <i>Blood</i> , 2021 , 138, 219-219	2.2	2
115	Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases. <i>Blood</i> , 2021 , 138, 3657-3657	2.2	0
114	Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN). <i>Blood</i> , 2021 , 138, 1096-1096	2.2	

113	Acute Myeloid Leukemia in the Context of Previous History of Cancer with or without Exposure to Chemotherapy or Radiotherapy. <i>Blood</i> , 2021 , 138, 3368-3368	2.2	0
112	Histopathologic Characterization of Vexas Syndrome. <i>Blood</i> , 2021 , 138, 4656-4656	2.2	
111	T-MDS Is a Distinct Clinical and Pathological Entity Characterized By Better Survival Compared to t-AML. <i>Blood</i> , 2021 , 138, 3377-3377	2.2	
110	Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA + venetoclax chemotherapy. <i>American Journal of Hematology</i> , 2021 , 96, E108-E111	7.1	3
109	Mayo Clinic experience with 1123 adults with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 46	7	1
108	Clinical, molecular, and prognostic comparisons between CCUS and lower-risk MDS: a study of 187 molecularly annotated patients. <i>Blood Advances</i> , 2021 , 5, 2272-2278	7.8	3
107	Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. <i>American Journal of Hematology</i> , 2021 , 96, 781-789	7.1	17
106	Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations. <i>American Journal of Clinical Pathology</i> , 2021 , 156, 679-690	1.9	2
105	PD-1/PD-L1 expression in extramedullary lesions of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 764-767	1.9	4
104	The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia - A Single Center Retrospective Study. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2021 , 11, 1-9	2.6	2
103	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. <i>Blood Cancer Journal</i> , 2021 , 11, 49	7	11
102	44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1944-1948	6.4	1
101	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021 , 127, 4421-4431	6.4	1
100	De novo isolated myeloid sarcoma: comparative analysis of survival in 19 consecutive cases. <i>British Journal of Haematology</i> , 2021 , 195, 413-416	4.5	1
99	Clinical Heterogeneity of the VEXAS Syndrome: A Case Series. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2653-2659	6.9	7
98	Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. <i>Blood Advances</i> , 2020 , 4, 5425-5430	7.8	10
97	A population-based study of chronic neutrophilic leukemia in the United States. <i>Blood Cancer Journal</i> , 2020 , 10, 68	7	7
96	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020 , 190, 244-248	4.5	1

95	Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1592-1600	1.9	6
94	A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. <i>American Journal of Hematology</i> , 2020 , 95, E257	7.1	2
93	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020 , 99, 513-518	3	1
92	Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients. <i>Blood</i> , 2020 , 136, 35-36	2.2	
91	A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015. <i>Blood</i> , 2020 , 136, 30-31	2.2	
90	Early Assessment of Treatment Response in Acute Myeloid Leukemia Using FLT PET/CT Imaging: A Trial of the ECOG-ACRIN Cancer Research Group (EAI141). <i>Blood</i> , 2020 , 136, 30-31	2.2	
89	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (Philadelphia chromosome like) B-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020 , 95, E68-E72	7.1	2
88	Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. <i>Annals of Hematology</i> , 2020 , 99, 2119-2124	3	2
87	Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia. <i>Blood Cancer Journal</i> , 2020 , 10, 121	7	7
86	Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. <i>American Journal of Hematology</i> , 2020 , 95, 1511-1521	7.1	28
85	Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients. <i>Leukemia</i> , 2020 , 34, 656-661	10.7	17
84	Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis. <i>Modern Pathology</i> , 2020 , 33, 334-343	9.8	6
83	Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. <i>International Journal of Cancer</i> , 2020 , 147, 3160-3167	7.5	11
82	Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model. <i>Blood Cancer Journal</i> , 2019 , 9, 12	7	28
81	Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experience. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2483-2487	1.9	2
80	3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 599-610	6.4	50
79	Patterns and utility of vitamin B12 and folate testing in patients with isolated thrombocytopenia. <i>Annals of Hematology</i> , 2019 , 98, 1993-1994	3	1
78	Etiologies of Extreme Thrombocytosis: A Contemporary Series. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1542-1550	5	5

77	Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1467-1474	6.4	8
76	Phenotypic Correlates and Prognostic Outcomes of TET2 Mutations in Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes: A Comprehensive Study of 504 Patients. <i>Blood</i> , 2019 , 134, 3005-3005	2.2	
75	Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB). <i>Blood</i> , 2019 , 134, 5441-5441	2.2	
74	Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias. <i>Blood</i> , 2019 , 134, 5406-5406	2.2	
73	Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial. <i>Blood</i> , 2019 , 134, 3863-3863	2.2	
72	Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy. <i>Annals of Hematology</i> , 2019 , 98, 331-337	3	2
71	Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes. <i>International Journal of Cardiology</i> , 2019 , 275, 6-12	3.2	18
70	Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. <i>American Journal of Hematology</i> , 2019 , 94, 5-9	7.1	3
69	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 990-999	1.9	5
68	Pre-anthracycline echocardiogram rarely changes treatment strategy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018 , 93, E144-E146	7.1	
67	GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. <i>Leukemia</i> , 2018 , 32, 1631-1642	10.7	117
66	Intravenous Bevacizumab for Refractory Hereditary Hemorrhagic Telangiectasia-Related Epistaxis and Gastrointestinal Bleeding. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 155-166	6.4	55
65	Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. <i>Leukemia</i> , 2018 , 32, 1200-1210	10.7	68
64	Prognostic interaction between bone marrow morphology and SF3B1 and ASXL1 mutations in myelodysplastic syndromes with ring sideroblasts. <i>Blood Cancer Journal</i> , 2018 , 8, 18	7	13
63	Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. <i>Leukemia</i> , 2018 , 32, 1189-1199	10.7	65
62	Momelotinib therapy for myelofibrosis: a 7-year follow-up. <i>Blood Cancer Journal</i> , 2018 , 8, 29	7	27
61	Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 229-232	1.9	0
60	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1117-e1122	3.3	1

59	Prognostic impact of ASXL1 mutations in patients with myelodysplastic syndromes and multilineage dysplasia with or without ring sideroblasts. <i>Leukemia Research</i> , 2018 , 71, 60-62	2.7	11
58	Mayo Alliance Prognostic Model for Myelodysplastic Syndromes: Integration of Genetic and Clinical Information. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 1363-1374	6.4	14
57	3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. <i>Blood</i> , 2018 , 132, 3035-3035	2.2	1
56	A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 µCi/Kg/Dose. <i>Blood</i> , 2018 , 132, 1457-1457	2.2	4
55	A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results. <i>Blood</i> , 2018 , 132, 1443-1443	2.2	
54	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018 , 132, 5510-5510	2.2	
53	Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronified after the FDA Approval Date of Anagrelide. <i>Blood</i> , 2018 , 132, 4287-4287	2.2	
52	Favorable Outcomes of Acute Leukemia of Ambiguous Lineage Treated with Hypercvad: A Multi-Center Retrospective Study. <i>Blood</i> , 2018 , 132, 2658-2658	2.2	
51	Clinical Correlates, Prognostic Impact and Survival Outcomes in Chronic Myelomonocytic Leukemia Patients with Myeloproliferative Neoplasm Associated-Driver Mutations. <i>Blood</i> , 2018 , 132, 3100-3100	2.2	
50	1,123 Consecutive Adults with Non-APL Acute Myeloid Leukemia: The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2689-2689	2.2	
49	Risk Factors for Leukemic Transformation Among 1,306 Patients with Primary Myelofibrosis: Mutations Predict Early Events. <i>Blood</i> , 2018 , 132, 3044-3044	2.2	
48	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018 , 93, E398-E401	7.1	1
47	A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status. <i>American Journal of Hematology</i> , 2018 , 93, E401-E404	7.1	2
46	Targeted next-generation sequencing in blast phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018 , 2, 370-380	7.8	55
45	High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia. <i>American Journal of Hematology</i> , 2017 , 92, E164-E166	7.1	2
44	Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience. <i>American Journal of Hematology</i> , 2017 , 92, 866-871	7.1	12
43	Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. <i>Blood Cancer Journal</i> , 2017 , 7, e550	7	14
42	Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey. <i>American Journal of Hematology</i> , 2017 , 92, E626-E627	7.1	1

41	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017 , 130, 891-891	2.2	5
40	Clinical and Serological Characteristics of Cold Autoimmune Hemolytic Anemia with Concomitant Cold Agglutinin and Donath-Landsteiner Antibodies. <i>Blood</i> , 2017 , 130, 927-927	2.2	
39	Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. <i>Blood Cancer Journal</i> , 2016 , 6, e405	7	24
38	Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival. <i>Blood</i> , 2016 , 128, 1123-1123	2.2	4
37	Characteristics and Outcome of Direct Antiglobulin Test-Negative Hemolytic Anemia: A Case Series. <i>Blood</i> , 2016 , 128, 2451-2451	2.2	1
36	Myeloid Sarcoma: The Mayo Clinic Experience of Ninety Six Case Series. <i>Blood</i> , 2016 , 128, 2798-2798	2.2	3
35	Outcome of Myelodysplastic Syndromes over Time in the US: A National Cancer Data Base Study from 2004-2013. <i>Blood</i> , 2016 , 128, 3604-3604	2.2	3
34	Outcome of Elderly Patients after Failure to Hypomethylating Agents Given As Frontline Therapy for Acute Myeloid Leukemia (AML): Single Institution Experience. <i>Blood</i> , 2016 , 128, 1617-1617	2.2	
33	Prognostic Relevance of Monocytopenia and Lymphocyte-to-Monocyte Ratio in Primary Myelodysplastic Syndromes. <i>Blood</i> , 2016 , 128, 1996-1996	2.2	
32	Subnormal Lymphocyte Count Predicts Inferior Survival in Myelodysplastic Syndromes: A Single Center Experience in 889 Patients. <i>Blood</i> , 2016 , 128, 5534-5534	2.2	0
31	Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. <i>Blood Cancer Journal</i> , 2016 , 6, e415	7	8
30	Deletion 5q is frequent in myelodysplastic syndrome (MDS) patients diagnosed with interstitial lung diseases (ILD): Mayo Clinic experience. <i>Leukemia Research</i> , 2016 , 50, 112-115	2.7	4
29	Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. <i>Leukemia</i> , 2015 , 29, 741-4	10.7	33
28	Primary Myelodysplastic Syndromes: The Mayo Clinic Experience With 1000 Patients. <i>Mayo Clinic Proceedings</i> , 2015 , 90, 1623-38	6.4	10
27	A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. <i>New England Journal of Medicine</i> , 2015 , 373, 908-19	59.2	219
26	Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib. <i>Leukemia</i> , 2015 , 29, 498-500	10.7	14
25	Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, e39-41	2	6
24	Busulfan for the Treatment of Myeloproliferative Neoplasms: The Mayo Clinic Experience. <i>Blood</i> , 2015 , 126, 4078-4078	2.2	1

23	Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis. <i>Blood</i> , 2015 , 126, 55-55	2.2	3
22	Momelotinib Therapy for Myelofibrosis: Impact on Long-Term Survival and Genotype Correlations. <i>Blood</i> , 2015 , 126, 4062-4062	2.2	
21	Molecular Correlates of Anemia in Primary Myelofibrosis. <i>Blood</i> , 2015 , 126, 4068-4068	2.2	
20	Survival Trends in Primary Myelodysplastic Syndromes: A Comparative Analysis of 1000 Patients By Year of Diagnosis and Treatment. <i>Blood</i> , 2015 , 126, 2875-2875	2.2	
19	Real-World Myelodysplastic Syndrome-unclassifiable and Its Comparison With Refractory Cytopenia With Multi-Lineage dysplasia and Refractory anemia <i>Blood</i> , 2013 , 122, 1574-1574	2.2	3
18	Clonal Evolution As Determined By Sequential Bone Marrow Karyotype Analysis During JAK Inhibitor Therapy For Myelofibrosis: Impact On Treatment Response and Overall and Leukemia-Free Survival. <i>Blood</i> , 2013 , 122, 2821-2821	2.2	1
17	Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. <i>Blood</i> , 2013 , 122, 394-394	2.2	13
16	Retrospective Comparison Of Survival and Leukemic Transformation In Myelofibrosis Patients Treated With Ruxolitinib Versus Momelotinib Versus Fedratinib Versus Pomalidomide. <i>Blood</i> , 2013 , 122, 4049-4049	2.2	1
15	Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. <i>Blood</i> , 2013 , 122, 662-662	2.2	10
14	BMS-911543, A Selective JAK2 Inhibitor: A Multicenter Phase 1/2a Study In Myelofibrosis. <i>Blood</i> , 2013 , 122, 664-664	2.2	15
13	Baseline Spleen Size and Mutations Involving ASXL1 and SRSF2 Predict Survival and Treatment Response In JAK Inhibitor Treated Myelofibrosis Patients. <i>Blood</i> , 2013 , 122, 4048-4048	2.2	
12	Monosomal Karyotype Predicts Adverse Prognosis In Patients With Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2013 , 122, 1334-1334	2.2	
11	Management Of PICC-Associated Thrombosis In Patients Receiving Chemotherapy For Hematologic Malignancies. <i>Blood</i> , 2013 , 122, 5000-5000	2.2	
10	Long-term outcome of pomalidomide therapy in myelofibrosis. <i>American Journal of Hematology</i> , 2012 , 87, 66-8	7.1	55
9	Lack of Prognostic Significance of Monosomal Karyotype and Absolute Lymphocyte Count At Diagnosis in Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2012 , 120, 1476 ^{2,3} 1476 ¹	2.2	
8	Evaluation of IPSS-Revised (IPSS-R) Cytogenetic Risk Stratification and Prognostic Impact of Monosomal Karyotype in 1,014 Patients with Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012 , 120, 423 ^{2,3} 423	2.2	
7	A phase-2 trial of low-dose pomalidomide in myelofibrosis. <i>Leukemia</i> , 2011 , 25, 301-4	10.7	97
6	Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials. <i>Blood</i> , 2011 , 118, 1759-1759	2.2	0

5	An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,. <i>Blood</i> , 2011 , 118, 3849-3849	2.2	10
4	IPSS Independent Prognostic Value of Plasma CXCL10, IL-7 and IL-6 Levels in De Novo Myelodysplastic Syndromes,. <i>Blood</i> , 2011 , 118, 3795-3795	2.2	
3	Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis. <i>Blood</i> , 2011 , 118, 1752-1752	2.2	1
2	Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study,. <i>Blood</i> , 2011 , 118, 3833-3833	2.2	
1	Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. <i>British Journal of Haematology</i> ,	4.5	2